Asset
Prademagene Zamikeracel
Abeona Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04227106 | phase3 | completed | 2020-01-10 | 2022-10-18 | Abeona Therapeutics, Inc | Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 125807 | BLA | Abeona Therapeutics Inc. |
Marketed products (1)
- zevaskyn